

Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival

Koen van Besien,¹ Parameswaran Hari,² Mei-Jie Zhang,² Hong-Tao Liu,³ Wendy Stock,³ Lucy Godley,³ Olatoyosi Odenike,³ Richard Larson,³ Michael Bishop,³ Amittha Wickrema,³ Usama Gergis,¹ Sebastian Mayer,¹ Tsiporah Shore,¹ Stephanie Tsai,¹ Joanna Rhodes,¹ Melissa M. Cushing,⁴ Sandra Korman,² and Andrew Artz¹

¹Department of Hematology/Oncology and Meyer Cancer Center – Stem Cell Transplant Program, Weill Cornell Medical College, New York, NY; ²Center for International Bone Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI; ³Section of Hematology/Oncology-Hematopoietic Cellular Therapy Program, University of Chicago, IL; and ⁴Department of Pathology – Cellular Therapy Laboratory, Weill Cornell Medical College, New York, NY, USA

©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.138594

Received: October 27, 2015.

Accepted: February 5, 2016.

Pre-published: February 11, 2016.

Correspondence: kov9001@med.cornell.edu

Supplementary Table: Comparison of outcomes without and with inclusion of 7 control patients 3/8 HLA match

Event	Initial Comparison			Excluding controls with 3/6 HLA match		
	N	Hazard Ratio (95% CI)	P-value Overall	N	Hazard Ratio (95% CI)	P-value Overall
ANC > 500/mm ³						
Study Cohort			0.007			0.007
Double UCB	193	1		185	1	
Haplo+Cord	97	1.42 (1.10 - 1.84)		97	1.43 (1.10 - 1.84)	
Platelet > 20x10 ⁹ /L						
Study Cohort			<0.0001			<0.0001
Double UCB	190	1		182	1	
Haplo+Cord	97	2.54 (1.88 - 3.41)		97	2.53 (1.87 - 3.41)	
Grade II – IV aGVHD						
Study Cohort						<0.0001
Double UCB	193	1		185	1	
Haplo+Cord	97	0.26 (0.15 – 0.45)		97	0.26 (0.16 – 0.45)	
Grade III – IV aGVHD						
Study Cohort			0.002			0.003
Double UCB	193	1		185	1	
Haplo+Cord	97	0.24 (0.09 – 0.60)		97	0.24 (0.09 – 0.60)	
cGVHD						
Study Cohort			0.0001			0.0001
Double UCB	189	1		182	1	
Haplo+Cord	97	0.06 (0.01 – 0.26)		97	0.07 (0.02 – 0.27)	

Event	Initial Comparison			Excluding controls with 3/6 HLA match		
	N	Hazard Ratio (95% CI)	P-value Overall	N	Hazard Ratio (95% CI)	P-value Overall
Treatment-Related Mortality						
Study Cohort			0.23			0.22
Double UCB	193	1		185	1	
Haplo+Cord	97	1.34 (0.83 – 2.16)		97	1.35 (0.83 – 2.19)	
Relapse/Progression						
Study Cohort			0.001			0.001
Double UCB	193	1		185	1	
Haplo+Cord	97	0.48 (0.31 – 0.75)		97	0.47 (0.30 – 0.74)	
Disease-Free Survival						
Study Cohort			0.13			0.12
Double UCB	193	1		185	1	
Haplo+Cord	97	0.78 (0.55 – 1.08)		97	0.77 (0.55 – 1.07)	
Overall Survival						
Study Cohort			0.85			0.75
Double UCB	193	1		185	1	
Haplo+Cord	97	0.97 (0.68 – 1.36)		97	0.95 (0.67 – 1.33)	
GVHD/Relapse Free Survival GRFS						
Study Cohort			0.002			0.002
Double UCB	187	1		180	1	
Haplo+Cord	97	0.63 (0.46 – 0.85)		97	0.63 (0.46 – 0.85)	